Rituximab treatment for relapsed autoimmune hemolytic anemia in Evans syndrome

Int J Hematol. 2003 Nov;78(4):335-6. doi: 10.1007/BF02983558.

Abstract

A case is reported of idiopathic relapsed autoimmune hemolytic anemia successfully treated with rituximab. A 43-year-old white male patient with past medical history of Evans syndrome was found to have recurrent autoimmune hemolytic anemia. Previous treatments included steroids, splenectomy, intravenous immunoglobulin, plasmapheresis, staphylococcal Protein A immunoadsorption (Prosorba column), and chemotherapeutic agents (cytoxan and vincristine). Rituximab was given weekly at 375 mg/m2 for 4 doses. The drug was well tolerated and the patient remains in remission 9 months after completion of therapy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Murine-Derived
  • Disease-Free Survival
  • Humans
  • Male
  • Recurrence
  • Remission Induction
  • Retreatment
  • Rituximab
  • Syndrome
  • Thrombocytopenia / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab